HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 03, 2021 (GLOBE NEWSWIRE) — Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) will be announcing its final results for the year ended December 31, 2020 on Thursday, March 4, 2021 at 12:00 noon Greenwich Mean Time (GMT) / 8:00 pm Hong Kong Time (HKT) / 7:00 am Eastern Standard Time (EST).
Analysts and investors are invited to join a conference call and audio webcast presentation with Q&A, conducted by Chi-Med management.
The conference call and audio webcast will take place at 1:00 pm GMT / 9:00 pm HKT / 8:00 am EST on Thursday, March 4, 2021 and will be webcast live via the company website at www.chi-med.com/investors/event-information/. The presentation will be available for downloading before the conference call begins. Details of the conference call dial-in will be provided in the financial results announcement and on the company website. A replay will also be available on the website shortly after the event.
About Chi-Med
Chi-Med (Nasdaq/AIM: HCM) is an innovative, commercial-stage, biopharmaceutical company committed, over the past twenty years, to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has a portfolio of nine cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. For more information, please visit: www.chi-med.com.
CONTACTS
| Investor Enquiries | |
| Mark Lee, Senior Vice President | +852 2121 8200 |
| Annie Cheng, Vice President | +1 (973) 567 3786 |
| Media Enquiries | |
| Americas – Brad Miles, Solebury Trout | +1 (917) 570 7340 (Mobile) bmiles@troutgroup.com |
| Europe – Ben Atwell / Alex Shaw, FTI Consulting | +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) Chi-Med@fticonsulting.com |
| Asia – Joseph Chi Lo / Zhou Yi, Brunswick | +852 9850 5033 (Mobile), jlo@brunswickgroup.com / +852 9783 6894 (Mobile), yzhou@brunswickgroup.com |
| Nominated Advisor | |
| Freddy Crossley / Atholl Tweedie, Panmure Gordon (UK) Limited | +44 (20) 7886 2500 |
Health Journey Addresses 'Best GLP-1 Supplement' Question with Akkermansia-Based Formula Analysis as Six-Month Costs Compare…
A Revolutionary ATCA/VME/VXI 3D-Flow Board: 512 Channels, >2,800 Programmable Operations—Scalable to >50,000 Operations on Each…
After President Trump's Marijuana Executive Order, Will the DEA Act-or Be Compelled by the Courts?"Despite…
Boards and executive buyers are raising the 2026 bar for all product and service rankings…
Boards and executive buyers are raising the 2026 bar for all product and service rankings…
Tampa based Celebrity Board-Certified Plastic Surgeon Dr. Meegan Gruber expands an interactive approach that allows…